• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.85% Nasdaq Up1.56%

    Novo Nordisk A/S (NVO)

    55.25 Up 0.28(0.51%) Oct 5, 4:03PM EDT
    ProfileGet Profile for:
    Novo Nordisk A/S
    Novo All
    Bagsvaerd, 2880
    Denmark - Map
    Phone: 45 44 44 88 88
    Fax: 45 44 49 05 55
    Website: http://www.novonordisk.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Other
    Full Time Employees:39,658

    Business Summary 

    Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S has a collaboration agreement with the Langer Laboratory for the development of next-generation drug delivery devices. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Novo Nordisk A/S

    Key Executives 
    Mr. Lars Rebien Sørensen , 61
    Chief Exec. Officer, Pres and Member of Exec. Management
    Mr. Jesper Brandgaard MSc, 52
    Chief Financial Officer, Exec. VP, Member of Exec. Management, Chairman of The Board - Novo Nordisk Engineering A/S and Chairman of The Board - Novo Nordisk IT A/S
    Dr. Mads Krogsgaard Thomsen Ph.D., 55
    Chief Science Officer, Exec. VP and Member of Exec. Management
    Mr. Jakob Riis , 49
    Exec. VP of China, Pacific & Marketing and Member of Exec. Management
    Mr. Lars Fruergaard Jørgensen , 49
    Chief of Staff, Exec. VP and Member of Exec. Management
    Mr. Jesper Hoiland M.Sc.,
    Exec. VP of Novo Nordisk USA and Member of Exec. Management
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.